Maolac says it will use the funds to build a facility with small-scale production capabilities.
Israeli foodtech startup Maolac says it recently raised $3.2 million in seed funding to create functional protein ingredients from bovine colostrum. The company will use the money to build a production facility.
The company uses “computational biology” to “identify and extract functional proteins from bovine colostrum,” which the company says is 95% equivalent to the nutrient-rich colostrum in human breast milk. The company is using bovine colostrum to create superfood products to benefit athletes, the elderly, and even pets. Its first product line is an anti-inflammatory product for humans.
“Initially, this [product line] will target athletes to help reduce muscle strain and improve recovery time,” explains a company press release. “The product line will also target the elderly, to support active living and improved mobility. It will form the basis for the next generation of gut health solutions for humans and pets to help prevent severe cases of gut inflammation.”
It explains: “Maolac’s technology relies on a bio-convergence platform for the discovery of proteins, based on proprietary machine learning and natural language processing search algorithms. Maolac has identified more than 1,500 known bioactive proteins in human breast milk. It discovered that bovine colostrum has over 400 homolog proteins with more than a 95% bio-similarity to human breast milk, which can be extracted. Maolac creates thousands of high-impact human functional milk protein mixtures, tailormade for various immune-boosting applications.”
The company sources its bovine colostrum from dairies where the colostrum is otherwise discarded.
In the press release, company CEO and cofounder Maya Ashkenazi-Otmazgin said, “The new investment will help Maolac disrupt the global immune-boosting market. The facility we’ll be able to build will help introduce our human functional milk proteins into new segments and enable the product to target a variety of food products for daily consumption.”
Survey finds a lack of enthusiasm about AI technology among food and beverage consumers
December 12th 2024The survey, commissioned by Ingredient Communications and conducted by SurveyGoo, found that 83% of respondent agreed that companies should declare on product labels when a product has been designed or manufactured with the assistance of AI technology.
Kelker Pharma to launch nutritional support system for GLP-1 medication users that features TriBsyn
December 11th 2024B&D Nutritional Ingredients Inc., an exclusive distribution partner of CarnoSyn Brands and Natural Alternatives International Inc., announced that its customer, Kelker Pharma, will be launching the “first science-backed nutritional support system” for GLP-1 medication users, called Nutrilinq Genesis.